Article 1. – Name
The society, established under the French law dated 1st July 1901 and the decree dated 16th August 1901, is called: “Société Européenne de Pharmacogénomique et Thérapie personnalisée – European Society of Pharmacogenomics and Personalised Therapy” (ESPT).
Article 2. – Objective
The European Society of Pharmacogenomics and Personalised Therapy is a non-profit-making organisation. Its objective is to promote training and research in pharmacogenomics and personalised therapy, in order to produce quality-controlled information for applications in clinical practice and for patients. It aims to facilitate contact between all those sharing its objectives, in particular those working in Europe. The Society will encourage and endeavour to integrate fundamental multidisciplinary approaches to research and transform them into clinical benefits, both for professional training and education of the general public, in all the areas of human pharmacogenomics, clinical pharmacology, laboratory medicine and personalised medicine.
Article 3. – Life-span
The Society has been founded with an unlimited life-span.
Article 4. – Registered address
The registered address of the Society is 30 rue Lionnois – Présidence de l’Université de Lorraine – UMR INSERM U1122 ; IGE-PCV– 54000 NANCY – FRANCE
Article 5. – Members of the Society
There are 7 categories of members.
5.1. Individual full members:
Membership will be open to any person working in the pharmacogenomic and personalised medicine field, preferably, but not exclusively, based in a European country.
5.2. Students full members:
Students, includingPhD students are included in this category (under 35 years old)
5.3. National organisations members:
The members of National societies or corresponding networks related to pharmacogenomics that have firmly agreed to collaborate with ESPT in the name of their society. A national representative full member is in charge of the society members
5.4. Associate members:
It is a category of individual members in the scientific groups
5.5. Corporate members
Any company involved in the field of pharmaceutics, biotechnology, laboratory medicine or related disciplines may become a corporate member.
5.6. Scientific Advisory Board members
Experts in the field of pharmacogenomics and personalised therapy proposed by any ESPT member and accepted by the General Assembly. They are nominated for a period of 4 years renewable.
5.7. Honorary members:
This distinction is awarded to those who have made an exceptional contribution to the field of pharmacogenomics and personalised therapy.
Collaboration with European and International Institutions
ESPT will sign agreement with European and International Institutions, foundations, research institutes and organisations working in the field for avoiding overlapping activities.
Article 6. – Subscriptions
Individual full members, students, corporate members, associate and national society members will pay an annual subscription, the amount of which will be determined by the Executive Board. The subscription for students may be set at a lower amount than that of other members.
Subscriptions will be waived for members of other categories, honorary and scientific advisory board members.
Subscriptions are given in euros, payable at the beginning of each civil year for each paying membership category.
Article 7. – General provisions
To join the Society, an applicant must be approved by the Executive Board which will confirm by a majority vote at each of its meetings on the applications for admission presented.
7.2. Loss of membership statutes
Membership of the Society may end:
– by voluntary resignation;
– by death;
– by the dissolution, closure or merger of an organisation which is a member;
– by in arrear of payment annual subscription for two consecutive years. The exclusions must be decided by the Executive Board by a majority vote after getting a statement of the member concerned. The member concerned may not take part in this vote and may not vote by procuration.
Article 8. – Activities
The Society organises, co-organises and supports meetings, symposia, conferences and other scientific meetings as well as educational programmes in order to produce information for applications in clinical practice and for patients in the field of pharmacogenomics and personalised therapy. A major event is the Society’s annual congress, which should preferably take place in the spring or autumn. A General Assembly will take place during this event. Other activities contributing to the Society’s objectives may also be undertaken, such as participation in grant applications, in clinical trials, multi-site trials, and evaluation of biomarkers, drawing up and preparing critical independent expert opinions recommendations appropriate to the Society’s areas of interest.
Article 9. – Publications
The Society will publish the programmes of its congresses and abstracts of the presentations. From time to time, the Society will also publish its committees’ reports, and directives and recommendations after ratification by the Executive Board. At present, the journal “Drug Metabolism and Personalised Therapy” (DMPT), published by De Gruyter, is the Society’s official journal. The members of the Executive Board will work closely with the chief editor of DMDI and will encourage members of the Society to submit their work to the journal. The Society reserves the right to periodically examine and modify its publication strategies.
Article 10. – The General Assembly
All members in good standing may take part in the General Assembly. General Assembly may be ordinary or extraordinary. Meetings considered as extraordinary will be those where decisions are to be taken concerning modification of the statutes and winding up the Society.
A General Assembly will take place at least once a year and whenever necessary. The date and place of the General Assembly will be communicated one year prior. Notices to members convening a meeting must show the agenda and should to be sent (either by letter or electronic mail) to all members at least 15 days before the meeting. Minutes of a General Assembly will be taken to record decisions taken and acceptance of the budget. They will constitute an official document of the Society.
No quorum is required for Ordinary General Assembly. Decisions taken in an Extraordinary General Assembly will be valid if 30% of members in good standing are present or represented. If this quorum is not reached, the Extraordinary General Assembly will be reconvened and will constitute a quorum independent of the number of delegates.
Each member in good standing has one vote. A member may give written procuration to vote to another member. One member may not represent more than one other member. If the number of votes is equal, the President, or in case of absence, the president elect, will have the casting vote.
Ordinary decisions are taken by a simple majority of votes. Decisions in an Extraordinary General Assembly are taken with a two-thirds majority of the members present or represented.
The General Assembly will approve the budget and the accounts of the Society, elect or dismiss members of the Executive Board and may modify the articles of association and dissolve the Society. The agenda of the General Assembly must include: